EDAP TMS SA to Report Fourth Quarter and Full Year 2016 Results on April 3, 2017
14 Marzo 2017 - 5:31AM
EDAP TMS SA to Report Fourth Quarter and
Full Year 2016 Results on April 3, 2017
LYON, France, March 14, 2017 - EDAP TMS SA (NASDAQ: EDAP), the
global leader in therapeutic ultrasound, today announced that it
will release its financial results for the fourth quarter and year
ended December 31, 2016, after the close of the financial markets
on Monday, April 3, 2017.
An accompanying conference call will be conducted by Marc
Oczachowski, Chief Executive Officer, and Francois Dietsch, Chief
Financial Officer, to go over the results. The call will be held at
8:30 AM ET, on Tuesday, April 4, 2017. Please refer to the
information below for conference call dial-in information and
webcast registration.
Conference Details
Conference Date: Tuesday, April 4, 2017 8:30 AM ETConference
dial-in: 877-269-7756International dial-in: 201-689-7817Conference
Call Name: EDAP-TMS Fourth Quarter and Full Year 2016 Results
CallWebcast Registration: Click Here
Following the live call, a replay will be available on the
Company's website, www.edap-tms.com under "Investors
Information."
About EDAP TMS SA
EDAP TMS SA today markets Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and for
treatment of localized prostate cancer in the rest of the world.
HIFU treatment is shown to be a minimally invasive and effective
option for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm-HIFU is approved for
commercial distribution in Europe and some other countries
including Mexico, Chile, Brazil and Canada, and has received 510(k)
clearance by the U.S. FDA. The Company also markets an innovative
robot-assisted HIFU device, the Focal One®, dedicated to focal
therapy of prostate cancer. Focal One® is CE marked but is not FDA
approved. The Company also develops its HIFU technology for the
potential treatment of certain other types of tumors. EDAP TMS SA
also produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Important Cautions Regarding Forward-looking
Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved.Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
Investor Contact
CG CAPITALRich
Cockrell877.889.1972investorrelations@cg.capital
Company Contact
Blandine ConfortInvestor Relations / Legal Affairs EDAP TMS
SA+33 4 72 15 31 50bconfort@edap-tms.com
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024